Product logins

Find logins to all Clarivate products below.


Acute Myeloid Leukemia – Epidemiology – Epidemiology Dashboard

Clarivate Epidemiology’s coverage of AML comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the diagnosed incidence and diagnosed prevalence of AML for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the mature markets and Europe, and 10 years for the other countries we cover.

All forecast data are available on Clarivate’s Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods. In addition, we provide a graph depicting the patient flow between or within different disease states for the major mature pharmaceutical markets. These patient-flow diagrams are provided at the regional level but may be requested for any specific country or forecast year.

Clarivate Epidemiology’s AML forecast answers the following questions:

  • How will changes in the levels of exposure to known risk or protective factors affect the number of people living with a diagnosis of AML and the number of new diagnoses of AML?
  • Of all people diagnosed with AML, how many in each country across the major mature pharmaceutical markets are drug-treated?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of AML over the forecast period?

In addition to the total number of diagnosed AML incident cases for each forecast year, Clarivate Epidemiology provides at least 10 years of forecast data for the following AML populations:

  • Cytogenetic risk
  • Prevalent cases
  • Drug-treatable populations
  • Drug-treated populations
  • FLT3 mutations

Note: Coverage may vary by country.

Related Market Assessment Reports

Report
Multiple Myeloma – Landscape & Forecast – Disease Landscape & Forecast (G7)
The treatment of multiple myeloma is becoming increasingly complex. Sanofi’s Sarclisa received a label expansion for the first-line treatment of autologous stem-cell transplantation-ineligible…
Report
Multiple Myeloma – Geographic Focus: China – Multiple Myeloma – China In-Depth (China)
China’s multiple myeloma therapy market is evolving rapidly, driven by an increasing disease burden and advances in treatment options. Current therapies in China largely mirror global standards;…
Report
Paroxysmal Nocturnal Hemoglobinuria – Landscape & Forecast – Niche & Rare Disease Landscape & Forecast (US/EU5)
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare blood disorder in which the immune system attacks red blood cells and platelets. PNH is characterized by intravascular hemolysis, venous…
Report
Ocular Pain – Epidemiology – Mature Markets
Clarivate Epidemiology’s coverage of ocular pain comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy…
Report
Immune Thrombocytopenic Purpura – Current treatment – Treatment Algorithms: Claims Data Analysis – Immune Thrombocytopenic Purpura (US)
Immune thrombocytopenic purpura (ITP) is an autoimmune disorder characterized by a low platelet count, resulting in an increased risk of bleeding. Current therapies for ITP can be largely divided…